Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II Study of ATLCAR.CD30 for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma
NCT02690545Phase 2Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Aug 2016
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATLCAR in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Adverse Events at 6 weeks and Progression-Free Survival at 2 years. Started Aug 2016; status: active, not recruiting.
02
Drugs
ATLCAR
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02690545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690545.